Angioimmunoblastic T-cell lymphoma (AITL) is a rare, aggressive (fast-growing) form of peripheral T-cell lymphoma. It only accounts for around 1-2% of all non-Hodgkin lymphoma. It is one of the more common subtypes of mature T-cell lymphomas.
It can be more common in the elderly.
The clinical spectrum includes high fevers, generalised lymphadenopathy, a skin rash, and hepatosplenomegaly.
Treatment and prognosis
Despite advances in treatment regimens for AITL, prognosis remains poor with an overall 5-year median survival of 32%. 3
- 1. Rodríguez J, Conde E, Gutiérrez A et-al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur. J. Haematol. 2007;78 (4): 290-6. doi:10.1111/j.1600-0609.2007.00815.x - Pubmed citation
- 2. Lee HJ, Im JG, Goo JM et-al. Peripheral T-cell lymphoma: spectrum of imaging findings with clinical and pathologic features. Radiographics. 2003;23 (1): 7-26. doi:10.1148/rg.231025018 - Pubmed citation
- 3. Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood. 129 (9): 1095-1102. doi:10.1182/blood-2016-09-692541 - Pubmed
- overview of lymphoma
WHO classification of tumours of haematopoietic and lymphoid tissues
- Hodgkin lymphoma
- mature B-cell lymphoma
- mature T-cell and NK-cell lymphoma
- post-transplant lymphoproliferative/lymphoproliferation disorders
- location-specific lymphomas
- central nervous system
- head and neck lymphoma
- thoracic lymphoma
- gastrointestinal lymphoma
- hepatobiliary lymphoma
- genitourinary lymphoma
- musculoskeletal lymphoma
- cutaneous lymphoma
- lymphoma staging